Abstract:Purpose: To quantify interfractional anatomical variations and their dosimetric impact during the course of fractionated proton therapy (PT) of prostate cancer and to assess the robustness of the current treatment planning techniques.Methods: Simulation and daily in-room CT scans from ten prostate carcinoma patients were analyzed. PT treatment plans (78 Gy in 39 fractions of 2 Gy) were created on the simulation CT, delivering 25 fractions to PTV1 (expanded from prostate and seminal vesicles), followed by 14 boost fractions to PTV2 (expanded from prostate). Plans were subsequently applied to daily CT, with beams aligned to the prostate center in the sagittal plane. For five patients having a sufficiently large daily imaging volume, structure contours were manually drawn, and plans were evaluated for all CT sets. For the other five patients, the plans were evaluated for six selected fractions. The daily CT was matched to the simulation CT through deformable registration. The registration accuracy was validated for each fraction, and the three patients with a large number of accurately registered fractions were used for dose accumulation.Results: In individual fractions, the coverage of the prostate, seminal vesicles, and PTV1 was generally maintained at the corresponding prescription dose. For PTV2, the volume covered by the fractional prescription dose of 2 Gy (i.e., V2) was, on average, reduced by less than 3% compared to the simulation plan. Among the 225 (39 x 5 + 6 x 5) fractions examined, 15 showed a V2 reduction larger than 5%, of which ten were caused by a large variation in rectal gas, and five were due to a prostate shift in the craniocaudal direction. The fractional dose to the anterior rectal wall was found to increase for one patient who had large rectal gas volume in 25 of the 39 fractions, and another who experienced significant prostate volume reduction during the treatment. The fractional bladder dose generally increased with decreasing fullness. In the total accumulated dose for the three patients after excluding a few fractions with inaccurate registration due to a large amount of rectal gas (a condition inconsistent with RTOG protocol), 98.5%, 96.6%, and 98.2% of the PTV2 received the prescription dose of 78 Gy. The V75 and V70 of the anterior rectal wall and bladder both remained within tolerance.Conclusions: The results confirm that the PT planning techniques and dose constraints used at our institution ensure that target coverage to the prescription dose is maintained in the presence of interfractional anatomical variations. Dose coverage in individual fractions can be compromised, and normal tissue dose increased, due to deviations in the bladder and rectal volume compared to the simulation plans or progressive changes in the prostate volume during the treatment. Deviations from the plan can be reduced with efforts aimed at maintaining consistent daily patient anatomy. (C) 2011 American Association of Physicists in Medicine. [DOI: 10.1118/1.3604152]

Effect of Setup and Inter-Fraction Anatomical Changes on the Accumulated Dose in CT-guided Breath-Hold Intensity Modulated Proton Therapy of Liver Malignancies.

Impact Of Interfractional Motion On Hypofractionated Pencil Beam Scanning Proton Therapy And Vmat Delivery For Prostate Cancer

Evaluation Of The Dosimetric Impact Of Interfractional Anatomical Variations On Prostate Proton Therapy Using Daily In-Room Ct Images

Clinical Implementation of Intensity Modulated Proton Therapy for Thoracic Malignancies.

Incorporating Breath Holding and Image Guidance in the Adjuvant Gastric Cancer Radiotherapy: a Dosimetric Study

Intensity-modulated Proton Therapy (IMPT) Interplay Effect Evaluation of Asymmetric Breathing with Simultaneous Uncertainty Considerations in Patients with Non-Small Cell Lung Cancer.

Quantifying dose uncertainties resulting from cardiorespiratory motion in intensity-modulated proton therapy for cardiac stereotactic body radiotherapy

Evaluation and Mitigation of the Interplay Effects of Intensity Modulated Proton Therapy for Lung Cancer in a Clinical Setting.

SU‐F‐T‐205: Effectiveness of Robust Treatment Planning to Account for Inter‐ Fractional Variation in Intensity Modulated Proton Therapy for Head Neck Cancer

Robust Optimization in Intensity-Modulated Proton Therapy to Account for Anatomy Changes in Lung Cancer Patients

Effectiveness of Robust Optimization in Intensity-Modulated Proton Therapy Planning for Head and Neck Cancers

Impact of interplay effects on spot scanning proton therapy with motion mitigation techniques for lung cancer: SFUD versus robustly optimized IMPT plans utilizing a four-dimensional dynamic dose simulation tool

Effect of Anatomic Motion on Proton Therapy Dose Distributions in Prostate Cancer Treatment

Effects of interfractional motion and anatomic changes on proton therapy dose distribution in lung cancer.

Dosimetric Comparison of Intensity-Modulated Proton Radiotherapy Versus Intensity-Modulated Photon-Based Radiotherapy for Breast Cancer

On the interplay effects with proton scanning beams in stage III lung cancer.

Hepatic Arterial Phase and Portal Venous Phase Computed Tomography for Dose Calculation of Stereotactic Body Radiation Therapy Plans in Liver Cancer: a Dosimetric Comparison Study

Intensity-modulated Proton and Carbon-Ion Radiotherapy Using a Fixed-Beam System for Locally Advanced Lung Cancer: Dosimetric Comparison with X-Ray Radiotherapy and Normal Tissue Complication Probability (NTCP) Evaluation.

Comparison of dosimetry distribution between three-dimension conformal and intensity modulated plan integrated with breath motion in postoperative radiation of gastric cancer

Clinical Benefits of New Immobilization System for Hypofractionated Radiotherapy of Intrahepatic Hepatocellular Carcinoma by Helical Tomotherapy.

Impact of Positioning Errors on the Dosimetry of Breath-Hold-Based Volumetric Arc Modulated and Tangential Field-in-Field Left-Sided Breast Treatments